17th week of 2016 patent applcation highlights part 21 |
Patent application number | Title | Published |
20160115193 | NOVEL PURIFICATION OF ANTIBODIES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product). | 2016-04-28 |
20160115194 | PROTEIN PURIFICATION PROCESS - A method of purifying a target protein includes contacting a cell culture harvest or a protein preparation including at least one target protein with at least one fatty acid having 8 to 10 carbon atoms to form a mixture, contacting the mixture with one or more solids to form a mixture, the one or more solids comprise a cationic functional group, a metal binding functional group, or both, the metal binding functional group including a nitrogen-containing moiety selected from (1) a polyamine, (2) an imine, (3) an N-heterocycle, (4) an amino acid, (5) an N-hydroxyamide, (6), an arylamine, and combinations thereof, and separating solid materials after contacting the mixture with the one or more solids to provide a solution comprising the target protein. | 2016-04-28 |
20160115195 | PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES - The present invention provides an improved method for the purification of monoclonal antibody from cell culture. Process of purification of the desired monoclonal antibody comprises affinity, hydrophobic interaction and optionally ion exchange column chromatography. It provides more than 99% purity of the desired monoclonal antibody. | 2016-04-28 |
20160115196 | SELF-ASSEMBLED MICRO-AND NANOSTRUCTURES - The present invention discloses self-assembled bioadhesive anti-microbial, anti-fouling and/or anti-oxidant micro- and nano-structures comprising a plurality of amino acids or peptides, wherein each amino acid is an aromatic amino acid comprising a catecholic moiety, and/or each peptide comprises at least one aromatic amino acid comprising a catecholic moiety. Further disclosed are methods and kits for preparing these micro- and nano-structures. Further disclosed are uses of these micro- and nano-structures in pharmaceutical, cosmetic and medical devices applications. | 2016-04-28 |
20160115197 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. | 2016-04-28 |
20160115198 | METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF - Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed. | 2016-04-28 |
20160115199 | Cell Penetrating Peptides for Intracellular Delivery of Molecules - A cell-penetrating peptide characterized in that it comprises an amino acid sequence consisting of XWXRLXXXXXX (SEQ ID No: 5), wherein X in position 1 is beta-A or S; X in positions 3, 9 and 10 are, independently from each other, W or F; X in position 6 is R if X in position 8 is S, and X in position 6 is S if X in position 8 is R; X in position 7 is L or none; X in position 11 is R or none, and wherein X in position 7 is L if X in position 11 is none. | 2016-04-28 |
20160115200 | New Use for JNK Inhibitor Molecules for Treatment of Various Diseases - The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy. | 2016-04-28 |
20160115201 | PEPTIDES BINDING TO PARALLEL-STRANDED G-QUADRUPLEXES - This invention relates to a peptide comprising or consisting of the amino acid sequence of SEQ ID NO:1 or a derivative thereof. The present invention also relates to conjugates of said peptide, the use of the peptide or the conjugate as a medicament and to methods for the detection of parallel-stranded G-quadruplexes. | 2016-04-28 |
20160115202 | CHEMICAL SYNTHESIS AND SCREENING OF BICYCLIC PEPTIDE LIBRARIES - Disclosed herein are bicyclic peptide compounds, compositions comprising same, methods for making same, and libraries comprising same. The disclosed compounds, in various aspects, are useful for treating a variety of disorders, including inflammatory disorders, autoimmune disorders, and disorders of uncontrolled cellular proliferation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-04-28 |
20160115203 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF - Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits. | 2016-04-28 |
20160115204 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS - The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 2016-04-28 |
20160115205 | POLYVALENT HIV-1 IMMUNOGEN - The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1) particular, to a polyvalent vaccine for HIV-1 and to methods of making and using same. | 2016-04-28 |
20160115206 | Treponema Pallidum Triplet Antigen | 2016-04-28 |
20160115207 | GENETICALLY MODIFIED FILAMENTOUS FUNGI AND USES THEREOF - The present invention relates to a filamentous fungus comprising a genetic modification in one more hydrophobin genes and the use of the same as host cell for preparing a biosynthetic product. The present invention further pertains to a vector for and methods for generating said filamentous fungus. | 2016-04-28 |
20160115208 | USE OF AN IMMUNOMODULATORY PROTEIN FROM GANODERMA IN PROMOTING NEURITE OUTGROWTH - The inventors surprisingly found that an immunomodulatory protein from | 2016-04-28 |
20160115209 | CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 2016-04-28 |
20160115210 | COLORIMETRIC AND FLUORESCENT PROTEINS - The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths. | 2016-04-28 |
20160115211 | COMPOSITIONS AND METHODS FOR REGULATING ANGIOGENESIS AND CHOLESTEROL AND TREATING DYSLIPIDEMIA, ATHEROSCLEROSIS, CANCER AND INFLAMMATORY CONDITIONS - The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of ApoA-1 Binding Protein (APOAIBP, AIBP, or AI-BP), and methods for making and using them. In alternative embodiments, APOAIBP-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia. In alternative embodiments, pharmaceutical compositions and formulations of the invention that comprise APOAIBP nucleic acids and polypeptides or result in an increase in expression or activity of APOAIBP nucleic acids and polypeptides are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate a dyslipidemia, e.g., to treat, prevent, reverse and/or ameliorate conditions responsive to increasing cholesterol efflux from cells, including cardiovascular disease and atherosclerosis. | 2016-04-28 |
20160115212 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2016-04-28 |
20160115213 | Modified FGF-21 Polypeptides and Uses Thereof - Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner. | 2016-04-28 |
20160115214 | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF - This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. | 2016-04-28 |
20160115215 | Glucagon Analogs Exhibiting GIP Receptor Activity - Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range. | 2016-04-28 |
20160115216 | Method for Making Mature Insulin Polypeptides - This invention relates to an improved method for making mature human insulin or an analogue thereof by cultivating fungi cell comprising a DNA sequence encoding a precursor for human insulin or an analogue thereof, which precursor comprises a small connecting peptide. | 2016-04-28 |
20160115217 | COMPOSITIONS OF HUMANIZED NOTCH FUSION PROTEINS AND METHODS OF TREATMENT - This invention provides a fusion protein comprising a signal peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder. | 2016-04-28 |
20160115218 | Anti-Sense Oligonucleotides Targeted Against Exon 9 of IL-23R-alpha Gene and Method of Using Same to Induce Exon Skipping and to Treat Inflammatory Bowel Diseases - The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23Rα gene. Exon 9 skipping of the IL23Rα gene ultimately causes specific induction of a novel soluble truncated IL-23Rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a Δ9 protein which inhibits IL-23R-mediated cell signaling. More particularly, Δ9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease. | 2016-04-28 |
20160115219 | FACTOR VIII GLYCOFORMS - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 2016-04-28 |
20160115220 | PROTEOLYTIC RELEASE OF CELL SURFACE ANTIGENS FOR PHAGE BIOPANNING - The invention described herein features methods of isolating monoclonal antibodies or polypeptides that bind to a cell surface expressed antigen. The method of catch and release utilizes engineered protease site for cleavage antigen-antibody or antigen-polypeptide complexes. In some embodiments the protease cleavage site to cleave the complexes is an exogenous protease to mammalian cell. In various embodiments the protease cleavage site to cleave the complexes is an endogenous protease to mammalian cell. | 2016-04-28 |
20160115221 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY - The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))). | 2016-04-28 |
20160115222 | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES - Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections. | 2016-04-28 |
20160115223 | POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY - The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid. | 2016-04-28 |
20160115224 | FORM-SPECIFIC ANTIBODIES FOR NAG-1 (MIC-1, GDF-15), H6D AND OTHER TGF-BETA SUBFAMILY AND HEART DISEASE AND CANCER DIAGNOSES - A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer. | 2016-04-28 |
20160115225 | Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture - Methods are provided for controlling the levels of acidic species when a protein of interest is expressed by host cells. One particular example of an acidic species is methylglyoxal (MGO). Reduction of acidic species such as MGO may be achieved by regulating the glucose consumption of the cell culture or by modulating the cysteine/glutathione metabolic pathways. | 2016-04-28 |
20160115226 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TNF-ALPHA - This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes. | 2016-04-28 |
20160115227 | Administration of an Anti-Interleukin 12/23 Antibody for Treatment of Autoimmune Disease - The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as IL-1β and TNF-α, Th1-like cytokines IL-2 and IFN-γ, IL-17 (T | 2016-04-28 |
20160115228 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2016-04-28 |
20160115229 | Hybridoma Clones, Monoclonal Antibodies, and Methods of Use - The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier. | 2016-04-28 |
20160115230 | NOVEL ANTIBODY USEFUL IN NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS - The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-as-partate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis. | 2016-04-28 |
20160115231 | TREATMENT OF MAST CELL RELATED PATHOLOGIES - Methods of inhibiting activation of a mast cell and/or treating a disease induced by activation of a mast cell in a subject are provided. Accordingly there is provided a method comprising contacting a cancerous mast cell with an effective amount of a multivalent agent which binds and activates Siglec-7, thereby inhibiting activation of the cancerous mast cell. Also provided is a method comprising contacting a mast cell with an effective amount of an agent comprising: a first moiety which binds and activates Siglec-7; and a second moiety which binds activates a mast cell activating receptor, thereby inhibiting activation of the mast cell. Also provided are agents and compositions for and methods of inhibiting activation of a mast cell and/or treating a disease induced by activation of a mast cell in a subject. | 2016-04-28 |
20160115232 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF - Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response. | 2016-04-28 |
20160115233 | HIGH FUNCTIONAL BISPECIFIC ANTIBODY | 2016-04-28 |
20160115234 | Anti-GPIIB/IIIA Antibodies or Uses Thereof - The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies. | 2016-04-28 |
20160115235 | MONOCLONAL ANTIBODY DIRECTED AGAINST CXCR5 - The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers. | 2016-04-28 |
20160115236 | NEUTRALIZATION OF CD95 ACTIVITY BLOCKS INVASION OF GLIOBLASTOMA CELLS IN VIVO - The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue. | 2016-04-28 |
20160115237 | CELL SENESCENCE MARKERS AS DIAGNOSTIC AND THERAPEUTIC TARGETS - Provided are methods and agents for depleting senescent cells endogenous to a subject, involving administering to the subject a binding agent that is selectively toxic to senescent cells in an amount effective to reduce the number of such cells, wherein the binding agent binds selectively to a senescent cell surface protein having a misfolded conformation, relative to said protein in a native conformation. | 2016-04-28 |
20160115238 | CD20 Antibodies and Uses Thereof - CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively. | 2016-04-28 |
20160115239 | CD138-TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES - In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha. | 2016-04-28 |
20160115240 | USE OF SEMAPHORIN-4D INHIBITORY MOLECULES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASES - Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy. | 2016-04-28 |
20160115241 | HETERODIMERIC BISPECIFIC ANTIBODIES - Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety. | 2016-04-28 |
20160115242 | ANTI-CSPG4 FUSIONS WITH INTERFERON FOR THE TREATMENT OF MALIGNANCY - In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha or to an interferon beta (IFN-β) or to a mutant interferon beta, or to an interferon gamma (IFN-γ) or to a mutant interferon gamma. | 2016-04-28 |
20160115243 | ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore. | 2016-04-28 |
20160115244 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST KRAS - This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes. | 2016-04-28 |
20160115245 | SINGLE DOMAIN ANTIBODIES AGAINST SOD1 AND THEIR USE IN MEDICINE - The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS. | 2016-04-28 |
20160115246 | METHODS FOR INHIBITING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF PCSK9 - The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein. | 2016-04-28 |
20160115247 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS - This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes. | 2016-04-28 |
20160115248 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST STAT3 - This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes. | 2016-04-28 |
20160115249 | PHOSPHORIC ACID-ESTERIFIED FINE CELLULOSE FIBER AND METHOD FOR PRODUCING THE SAME - Objects of the present invention are to provide a phosphoric acid-esterified fine cellulose fiber of which slurry shows superior transparency, and to provide a method for producing a phosphorylated fine cellulose fiber showing superior transparency with good efficiency and high yield. According to the present invention, there is provided a phosphoric acid-esterified fine cellulose fiber, of which 0.2 mass % aqueous dispersion shows a solution haze of 15% or lower. | 2016-04-28 |
20160115250 | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof - This disclosure relates to synthetic oligosaccharide subunits of the | 2016-04-28 |
20160115251 | Heparan Sulphates - A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells whilst maintaining their pluripotency/multipotency. | 2016-04-28 |
20160115252 | Labeled Alginate Conjugates For Molecular Imaging Applications - Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents. | 2016-04-28 |
20160115253 | CHEMICAL CONVERSION PROCESS - The invention relates to a chemical conversion process and to a process for removing particles from a reaction mixture. The chemical conversion process of the invention comprises plasmonic heating of a reaction mixture, which reaction mixture comprises at least a one component and plasmonic particles, by exposing said reaction mixture to light comprising one or more wavelengths which are absorbed by at least part of the plasmonic particles, thereby controlling the reaction rate of one or more chemical reactions. | 2016-04-28 |
20160115254 | HYDROGENATION CATALYST AND PROCESS FOR PRODUCING OLEFIN POLYMER - The present invention provides a hydrogenation catalyst, which can produce an olefin polymer having a higher molecular weight, and a process for producing an olefin polymer having a higher molecular weight, by controlling hydrogen concentration in a polymerization reaction system efficiently in polymerizing an olefin in the presence of hydrogen. There is provided a hydrogenation catalyst formed by contacting the undermentioned component (A), the undermentioned component (B), and the undermentioned component (C). There is further provided a process for producing an olefin polymer characterized by polymerizing an olefin in the presence of hydrogen, the undermentioned component (A), the undermentioned component (B), and the undermentioned component (D). Component (A): a titanocene compound; Component (B): a silicon compound represented by the undermentioned general formula [1]: Si(OR | 2016-04-28 |
20160115255 | Radically Coupled Resins and Methods of Making and Using Same - A radically coupled polymer having a density of from about 0.915 g/ml to about 0.975 g/ml characterized by a crossover modulus that is equal to or less than y | 2016-04-28 |
20160115256 | Polymerization Process to Make Low Density Polyethylene - A high pressure polymerization process to form an ethylene-based polymer comprises the steps of:
| 2016-04-28 |
20160115257 | Catalyst component for olefin polymerization, catalyst, and use thereof - The present disclosure provides a solid catalyst component for olefin polymerization, comprising magnesium, titanium, a halogen, and an electron donor, wherein the electron donor is at least one selected from the group consisting of diol diester compounds as shown in Formula (I). The catalyst according to the present disclosure has significantly improved polymerization activity, hydrogen response, and stereoselectivity. According to the present disclosure, when the catalyst system containing a diol diester compound as shown in Formula (I) of the present disclosure is used in olefin polymerization, the catalyst shows good comprehensive performance, including high catalytic activity. In particular, in the presence of highly concentrated hydrogen, the catalyst has an improved hydrogen response and/or isotacticity of the polymers obtained can be significantly improved. The catalyst of the present disclosure is beneficial for obtaining polymers with a high melt index and high isotacticity, and for development of polymers of different grades. | 2016-04-28 |
20160115258 | POLYPROPYLENE WITH EXTREME BROAD MOLECULAR WEIGHT DISTRIBUTION - Polypropylene having a melt flow rate MFR | 2016-04-28 |
20160115259 | NON-HALOGEN FLAME RETARDANT POLYMERS - Non-halogenated monomers that can be polymerized into flame retardant polymers, and processes to produce the monomers and polymers is provided. In a simplest aspect, there is provided a monomer composition that can comprise a) a group derived from one of a (meth)acrylic acid, (meth)acrylamide, or vinylbenzene, b) a polyphosphate moiety, and c) an amine species. In the monomer composition, the ethylenically unsaturated monomer of (a) is covalently bonded directly or through a linking group to the moiety of b), forming a precursor monomer unit. The amine species of c) is in complex with the precursor monomer unit. The polymer can be a homopolymer of the monomer composition, or a copolymer of the monomer composition having varying a), b) and c). In one embodiment, the polymer can additionally comprise ethylenically unsaturated monomers not covalently bonded to a polyphosphate moiety and/or can be cross-linked with a cross-linking agent such as resorcinol. | 2016-04-28 |
20160115260 | Oxalic Acid Diamides As Modifiers For Polyolefin Catalysts - The present invention relates to the use of oxalic acid diamides as modifiers in conjunction with solid Ziegler-Natta type catalyst in processes in which polyolefins such as polypropylene are produced. The modified catalyst compositions produce polypropylene with good productivity and higher sterospecificity than systems without such modification. | 2016-04-28 |
20160115261 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A solid catalyst component for the polymerization of olefins comprising Mg, Ti, Cl and at least an electron donor compound which is the reaction product obtained by bringing into contact a Mg compound and a Ti compound having at least a Ti-halogen bond with an electron donor selected from specific diphenol derivatives. | 2016-04-28 |
20160115262 | PROPYLENE COPOLYMER FOR THIN-WALL PACKAGING - Propylene copolymer having a comonomer content in the range of 2.0 to 11.0 mol.-% and a melt flow rate MFR | 2016-04-28 |
20160115263 | Ethylene-Propylene Copolymeric Compositions With Long Methylene Sequence Lengths - This invention relates to methods to prepare and compositions pertaining to branched ethylene-propylene copolymers that include at least 50% ethylene content by weight as determined by FTIR; a g′ | 2016-04-28 |
20160115264 | Polymers with Improved Processability for Pipe Applications - A crosslinked metallocene-catalyzed polyethylene copolymer having a higher molecular weight (HMW) component and lower molecular weight (LMW) component wherein the HMW component is present in an amount of from about 10 wt. % to about 30 wt. % and wherein the LMW component is present in an amount of from about 70 wt. % to about 90 wt. %. | 2016-04-28 |
20160115265 | METAL COMPLEX WITH A LEWIS BASE LIGAND - A metal complex of the formula (1) | 2016-04-28 |
20160115266 | PROCESS FOR THE PREPARATION OF A PROPYLENE POLYMER - A process for the preparation of a propylene polymer in a multistage polymerisation process in the presence of a single site catalyst, said process comprising: (I) in a prepolymerisation step prepolymerising a single site catalyst in the presence of propylene and optionally at least one C2-10 alpha olefin comonomer and in the presence of hydrogen or in the absence of hydrogen; (II) in a slurry polymerisation step, polymerising propylene and optionally at least one C2-10 alpha olefin comonomer, with the pre-polymerised catalyst of step (I) in the presence of hydrogen; and subsequently (III) in a gas polymerisation step polymerising propylene and optionally at least one C2-10 alpha olefin comonomer, in the presence of catalyst and polymer from step (II) and optionally in the presence of hydrogen so as to form a propylene homopolymer or copolymer; wherein the amount of hydrogen fed to the pre-polymerisation step (I) is at most 15% of the total amount of hydrogen fed to steps (I) and (II) of the polymerisation process. | 2016-04-28 |
20160115267 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF - The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) | 2016-04-28 |
20160115268 | Quaternary Phosphonium Coated Surfaces and Methods of Making the Same - Disclosed herein is a composition comprising a substrate with functionalized surface covalently bound to an anti-infective agent, such as a quaternary phosphonium compound with anti-bacterial activity against a broad range of bacteria, methods of synthesizing an anti-infective composition, and its resultant antimicrobial performance. | 2016-04-28 |
20160115269 | PROCESS FOR PRODUCING HYDROGENATED BLOCK COPOLYMER, HYDROGENATED BLOCK COPOLYMER OBTAINED BY THE PROCESS, AND COMPOSITION THEREOF - The present invention relates to a method for producing a hydrogenated block copolymer, including the steps of: (a) forming a block copolymer by allowing a living polymer having a specific structure to react with a tetra- or more functional silane coupling agent; (b) hydrogenating the block copolymer to form a hydrogenated block copolymer; (c) isolating the resultant hydrogenated block copolymer; and (d) deactivating a functional group in the silane coupling agent and/or an unreacted functional group present in a coupling agent residue in the block copolymer or the hydrogenated block copolymer prior to the step (c), in which the number of functional groups derived from the coupling agent in the hydrogenated block copolymer recovered in the step (c) is 1.5 or less per block copolymer molecule; a hydrogenated block copolymer obtained by the method; and a composition containing the hydrogenated block copolymer. | 2016-04-28 |
20160115270 | PROCESS FOR PREPARING POLYOXYMETHYLENE - The patent application relates to a process for preparing polyoxymethylene by polymerization of a reaction mixture (R | 2016-04-28 |
20160115271 | CYANATE ESTER COMPOUND, CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND, AND CURED PRODUCT OF SAID COMPOSITION - The cyanate ester compound of the present invention is obtained by cyanating a modified naphthalene formaldehyde resin. | 2016-04-28 |
20160115272 | SUPRAMOLECULAR BIODEGRADABLE POLYMER - The present invention relates to a supramolecular biodegradable polymer comprising a quadruple hydrogen bonding unit (abbreviated herein as “4H-unit”), a biodegradable backbone and hard blocks and a process for preparing such a supramolecular biodegradable polymer. The supramolecular polymer is specifically suitable for biodegradable articles such as biomedical implants that need high strength and/or elasticity, e.g. medical implants in the cardio-vascular field. | 2016-04-28 |
20160115273 | HIGH-MOLECULAR LIQUID CRYSTAL MATERIAL FOR FRAME OF LIQUID CRYSTAL DISPLAY, FRAME AND MANUFACTURING METHOD - The invention provides a high-molecular liquid crystal material for a frame of a Liquid Crystal Display (LCD), which is prepared by cross-linking and polymerizing a group which includes terephthalic acid and an alcohol which includes carbon-carbon double bonds, wherein, the group which includes terephthalic acid is any one of terephthalic acid, ortho-alkyl-terephthalic acid or meta-alkyl-terephthalic acid; the alcohol which includes carbon-carbon double bonds is any one of vinyl alcohol, vinyl alcohol with alkyl, or conjugated vinyl alcohol. The high-molecular liquid crystal material improves the steric hindrance among the molecules, and prevents from reacting with the liquid crystal small molecules to form a coordination complex; the high-molecular liquid crystal material has high stability, and cannot form a solid state under a certain molecular weight, thus improving the flexibility and being beneficial for the coating process. | 2016-04-28 |
20160115274 | CARBOXYL FUNCTIONAL CURABLE POLYESTERS CONTAINING TETRA-ALKYL CYCLOBUTANEDIOL - A curable polyester resin composition containing residues of:
| 2016-04-28 |
20160115275 | Monomers Issued From Renewable Resources and Process for Polymerising Them - Polycarbonates prepared from carbonate monomers derived from the biomass are synthesized in the presence of an organometallic transfer agent and an alcohol. The number average molecular weight Mn of the final polymer increases with increasing the monomer/alcohol ratio. | 2016-04-28 |
20160115276 | TRANSPARENT POLYIMIDE AND PRECURSOR THEREOF - Provided is a polyimide excellent in heat resistance and colorless transparency and also excellent in flexibility and ultraviolet ray transmittance. The polyimide includes a structural unit represented by Formula (1a) and a structural unit represented by Formula (1b) wherein R is a specific aromatic group. | 2016-04-28 |
20160115277 | POLYIMIDE POLYMER, POLYIMIDE FILM, AND FLEXIBLE COPPER-COATED LAMINATE - A polyimide polymer represented by the following formula 1 is provided. | 2016-04-28 |
20160115278 | HIGH PERFORMANCE POLYMER AND PROCESS THEREFOR - A polymeric material process includes increasing a mobility within a polymer to enables specific alignment of polymer chains. | 2016-04-28 |
20160115279 | ACETOACETYL-FUNCTIONAL SILICON-BASED RESIN AND PROCESS FOR PREPARING THE SAME - An acetoacetyl-functional silicon-based resin includes at least a fraction with a branched molecular skeleton containing silicon atoms and acetoacetyl functional groups chemically bonded to the branched molecular skeleton. The acetoacetyl functional silicon-based resin can be used to formulate coating compositions. | 2016-04-28 |
20160115280 | SULFATED BETA-O4 LOW MOLECULAR WEIGHT LIGNINS - Low molecular weight sulfated beta-O4 lignin (SbO4L) are potent inhibitors of coagulation with high selectivity. | 2016-04-28 |
20160115281 | LIGNIN PRODUCT AND PROCESS FOR MAKING SAME - There is provided a process for recovery of lignin from black liquor that contains either soluble or dispersed lignin, generating a “liquid-lignin” at high yield. Lignin at elevated pH is precipitated by reducing the pH of the black liquor stream with carbon dioxide, at elevated temperature and pressure, creating two bulk fluid phases: a dense liquid-lignin phase and a light lignin-depleted phase. The dense liquid-lignin phase is separated and washed with a strong acid to displace metal cations from the lignin, creating a low-salt, randomly shaped lignin. If needed, especially for lignin recovered from kraft papermaking black-liquor streams, an oxidation step is included to eliminate negative odor for high value green chemistry applications. | 2016-04-28 |
20160115282 | Articles Having Improved Clarity, Prepared from Propylene-Ethylene Copolymers - Molded articles are prepared from propylene-ethylene copolymers and exhibiting improved clarity and strength properties. Articles prepared include bottles and other thin-walled articles. The articles are prepared using an isotactic propylene-ethylene random copolymer resin having an ethylene content of from about 0.5 to about 3 percent by total weight of copolymer, with a xylene solubles content of less than about 1.5 percent. The injection molded article may exhibit less than about 20 percent haze, as determined by ASTM D1003, at a thickness of about 0.08 inch (2.03 mm). Articles may also be prepared from similar copolymers having an ethylene content greater than about 3 percent by total weight of copolymer, with a xylene solubles content of less than about 4 percent by total weight of copolymer. These articles may exhibit less than about 13 percent haze, as determined by ASTM D1003, at a thickness of about 0.08 inch (2.03 mm). | 2016-04-28 |
20160115283 | EPOXY-RESIN COMPOSITION FOR FIBER-MATRIX SEMIFINISHED PRODUCTS - The present invention relates to an epoxy-resin composition as matrix component for sheet molding compounds (SMC) and/or bulk molding compounds (BMC), comprising a resin component comprising at least one epoxy resin and a hardener component comprising at least one imidazole compound and at least one latent hardener. In said epoxy-resin composition, the amount of the imidazole compounds used is in the range from 0.007 to 0.025 mol per mole of epoxy groups of the entire composition, and the total amount of primary amine groups optionally comprised does not exceed a proportion of 0.09 mol per mole of epoxy groups of the entire composition. The invention also relates to a fiber-matrix-semifinished-product composition (SMC composition or BMC composition) with, as matrix component, the epoxy-resin composition mentioned, and with, suspended therein, short reinforcement fibers with an average length of from 0.3 to 5.0 cm. The fiber-matrix-semifinished-product composition can be produced via mixing of the constituents, whereupon the composition thickens. The resultant thickened product (semisolid fiber-matrix semifinished product) features comparatively short maturing time and comparatively long available operating time. The invention also relates to the corresponding semisolid fiber-matrix composite, in particular to the semisolid SMC and to the corresponding cured fiber-matrix semifinished product, in particular the cured SMC. Finally, the invention also relates to a screening process for identifying epoxy-resin-based compositions which are suitable for use as thermoset matrix for producing SMC. | 2016-04-28 |
20160115284 | HIGH CLARITY AND STRENGTH POLYETHYLENE FILMS - A film having an A/B/A structure comprising an layer A and a layer B. The layer A is present in an amount ranging from 25 to 65 wt. %, based upon the total weight of the A/B/A structure, and the layer A comprises a first A layer and a second A layer each independently comprise linear low density polyethylene. The layer B is present in an amount ranging from 35 to 75 wt. %, based upon the total weight of the A/B/A structure, and the layer B, which comprises high density polyethylene, is positioned between the first A layer and the second A layer. | 2016-04-28 |
20160115285 | POLYETHYLENE COMPOSITIONS AND FILMS FORMED THEREFROM - A polyethylene composition comprising an ethylene/α-olefin copolymerized linear low density polyethylene, wherein the polyethylene composition has a Mw of from 100,000 g/mol to 200,000 g/mol, a Mw/Mn of from 4.0 to 9.0, a Mz/Mw of from 4.0 to 7.0, and a Mz+1/Mw of from 4.5 to 13.5, is provided. A film formed of the polyethylene composition is also provided. | 2016-04-28 |
20160115286 | HYDROPHILIC FLUOROPLASTIC SUBSTRATES - Hydrophilic fluoroplastic substrates and methods of making hydrophilic fluoroplastic substrates from 4-acryloylmorpholine are disclosed. | 2016-04-28 |
20160115287 | THERMOPLASTIC POLYMERS - Thermoplastic polymers, for example fluoropolymers, are foamed by use of a solid formulation comprising thermoplastic polymer and an oxalate compound which includes a moiety selected from potassium, calcium, titanium, iron, cobalt, nickel, copper, zinc, zirconium and barium. | 2016-04-28 |
20160115288 | CO2 CONTAINING FOAMS AND RELATED METHODS - The present invention provides methods for producing polyurethane foam compositions. Such methods include mixing an A-side composition, a B-side composition, and CO | 2016-04-28 |
20160115289 | ELASTIC RIGID FOAM HAVING IMPROVED TEMPERATURE STABILITY - The invention relates to temperature-stable rigid foams which can be cold formed and have a density of 0 to 100 kg/m (according to DIN 53420), an elongation at break (according to DIN 53430) of 12 to 35%, a percentage of open cells (according to DIN ISO 4590-86) of 51% to 98% and a storage module of the foam (according to DIN EN ISO 6721 B:1996-12) in the temperature range of 60 DEG to 190 DEG C of, on average, greater or equal 0.1 MPa, and to composite materials produced with said foams. | 2016-04-28 |
20160115290 | Method and a Device for Preparation of Expanded Microspheres - The invention relates to a method and a device for the preparation of expanded thermoplastic microspheres from unexpanded thermally expandable thermoplastic microspheres comprising a thermoplastic polymer shell encapsulating a blowing agent. The method comprises: (a) feeding a slurry of such expandable thermoplastic microspheres in a liquid medium into a heating zone; (b) heating the slurry in the heating zone, without direct contact with any fluid heat transfer medium, so the expandable microspheres reach at least a temperature at which they would have started to expand at atmospheric pressure, and maintaining a pressure in the heating zone sufficiently high so the microspheres in the slurry do not-fully expand; and, (c) withdrawing the slurry of expandable microspheres from the heating zone into a zone with a pressure sufficiently low for the microspheres to expand. | 2016-04-28 |
20160115291 | Polyolefin Material having a Low Density - A polyolefin material that is formed by solid state drawing of a thermoplastic composition containing a continuous phase that includes a polyolefin matrix polymer and nanoinclusion additive is provided. The nanoinclusion additive is dispersed within the continuous phase as discrete nano-scale phase domains. When drawn, the nano-scale phase domains are able to interact with the matrix in a unique manner to create a network of nanopores. | 2016-04-28 |
20160115292 | SEPARATION METHOD AND SEPARATION DEVICE USED THEREIN - Provided are a separation method and a separation device used therein with which plastic and aluminum can be separated. The separation method includes a first heating step, and a first heat insulation step. In the first heating step, a processing target, which is accommodated in a container and contains aluminum and one or more types of plastic, is heated to a first temperature. The first temperature is a temperature that is less than the melting point of the aluminum and is greater than or equal to the melting point of at least one type of the plastic. Thus, the at least one type of plastic is melted. In the subsequent first heat insulation step, the processing target is kept at the first temperature. The heat insulation is continued until the aluminum is precipitated in the container and separated from the melted plastic. | 2016-04-28 |